DDInter927 DDInter1000
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with
Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults. It is currently approved to also treat newly diagnosed acute myeloid leukemia in older adults in combination [azacitidine] or as monotherapy, as well as locally advanced or metastatic cholangiocarcinoma and relapsed or refractory myelodysplastic syndromes in adults. The drug is only effective in patients with a susceptible IDH1 mutation. In February 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of ivosidenib and recommended it be granted marketing authorization for the treatment of acute myeloid leukemia and cholangiocarcinoma. It was fully approved by the EMA in May 2023.
Ivosidenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mirabegron
Ivosidenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tofacitinib
Ivosidenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zanubrutinib
Ivosidenib {u} may lead to a major life threatening interaction when taken with {v} Alfuzosin
Ivosidenib {u} may lead to a major life threatening interaction when taken with {v} Oliceridine
Ivosidenib may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Ivosidenib may lead to a major life threatening interaction when taken with Alfuzosin
Ivosidenib may lead to a major life threatening interaction when taken with Oliceridine